Oruka Therapeutics Secures Major Funding to Advance Clinical Pipeline

Oruka Therapeutics has positioned itself for significant growth following a substantial $164 million capital infusion. According to SEC filings made public on November 5, the biotechnology firm obtained this funding through a private investment in public equity (PIPE), providing operational financing expected to last through 2027.

The capital raise, which closed on September 19, delivered a powerful $164 million to Oruka’s balance sheet. The transaction involved the placement of 10,933,405 shares at $15 per share, accompanied by preferred options for an additional 1,066,666 shares. This financial reinforcement arrives at a critical juncture for the company, which had previously faced questions about its ability to secure funding beyond mid-2025.

• $164 million total financing secured
• $15 Read more...